Education
About Us
Working with TipRanks
Follow Us
Y-Mabs Therapeutics (YMAB)
:YMAB
YMAB Stock Chart & Stats
Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Y-Mabs Therapeutics News
YMAB FAQ
What was Y-Mabs Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Y-Mabs Therapeutics’s market cap?
Currently, no data Available
When is Y-Mabs Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Y-Mabs Therapeutics’s earnings last quarter?
Currently, no data Available
Is Y-Mabs Therapeutics overvalued?
According to Wall Street analysts Y-Mabs Therapeutics’s price is currently Undervalued.
Does Y-Mabs Therapeutics pay dividends?
Y-Mabs Therapeutics does not currently pay dividends.
What is Y-Mabs Therapeutics’s EPS estimate?
Y-Mabs Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Y-Mabs Therapeutics have?
Currently, no data Available
What happened to Y-Mabs Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Y-Mabs Therapeutics?
Currently, no hedge funds are holding shares in YMAB
Company Description
Y-Mabs Therapeutics
Y-Mabs Therapeutics, Inc. (YMAB) is a biopharmaceutical company focused on the development and commercialization of innovative antibody-based products for the treatment of cancer. The company specializes in developing therapies for pediatric oncology and orphan diseases, using its proprietary radioimmunotherapy platform aimed at targeting tumors with precision. Its lead product candidates target neuroblastoma, a rare cancer affecting children, as well as other solid tumor indications.
Technical Analysis
Ownership Overview
―
Insiders
8.39%
Mutual Funds
― Other Institutional Investors
87.26% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---